Adenylyl Cyclase Increases Survival in Cardiomyopathy
- 23 April 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (16) , 1989-1994
- https://doi.org/10.1161/01.cir.0000014968.54967.d3
Abstract
Background— To test the hypothesis that increased cardiac adenylyl cyclase type VI (ACVI) content, which results in increased cAMP generation, would increase survival in cardiomyopathy, we crossbre...Keywords
This publication has 16 references indexed in Scilit:
- Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathyJournal of Clinical Investigation, 2001
- Cytoplasmic Signaling Pathways That Regulate Cardiac HypertrophyAnnual Review of Physiology, 2001
- Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of β‐adrenergic receptor dysfunction in the Gαq overexpressing mouseFEBS Letters, 1999
- Low- and high-level transgenic expression of β 2 -adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing miceProceedings of the National Academy of Sciences, 1999
- Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted miceProceedings of the National Academy of Sciences, 1998
- Transgenic Gαq overexpression induces cardiac contractile failure in miceProceedings of the National Academy of Sciences, 1997
- cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardiumCardiovascular Research, 1994
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991
- Xamoterol in severe heart failureThe Lancet, 1990
- Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failureAmerican Heart Journal, 1986